Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Iron supplements for preventing or treating anemia among children in malaria-endemic areas

Iron supplements do not increase the likelihood of contracting malaria and should not be withheld from children at risk of the disease, despite World Health Organisation (WHO) guidelines to the contrary, a new review by Cochrane Researchers suggests.

7 Jul 2009

First baby born after new ovarian transplant technique

A new technique for transplanting the ovaries of women who have lost their fertility as a result of cancer treatment was outlined to the 25th annual conference of the European Society of Human Reproduction and Embryology today (Monday 29 June).

29 Jun 2009

White House: Shield biotech drugs from generics for only seven years

White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.

29 Jun 2009

Prevalence and predictors of antioxidant supplement use during breast cancer treatment

A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown.

9 Jun 2009

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

5 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Combination of gene therapy and induced pluripotent stem cells cure human genetic disease in vitro

A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic.

31 May 2009

Hospital refuses admission to young adults with thalassemia and sickle cell disease

Young adults with thalassemia and sickle cell diease have been trying for up to 10 years to gain admission to the only adult hospital program in central and southwestern Toronto specialized to treat their blood disorders. Since 1999, the Toronto General Hospital (TGH) has restricted the inherited blood disorders program to 99 patients requiring blood transfusions. As a result, about 150 young adults with complex disorders receive blood transfusions at the Hospital for Sick Children but no adult services.

25 May 2009

Overnight dialysis more convenient and effective

Overnight dialysis is more convenient for some patients and offers significant benefits over shorter daytime treatments, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

22 May 2009

Methylene blue in combo with new malaria drugs curbs the spread of malaria parasites

New combinations of agents based on the oldest synthetic malaria drug, the methylene blue stain, can curb the spread of malaria parasites and make a significant contribution to the long-term eradication called for by the international "Roll Back Malaria Initiative."

20 May 2009

Rituximab linked to viral brain infection

The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares.

18 May 2009

Pathway opens up cure for Fanconi anemia

In patients with Fanconi anaemia (FA) one of the DNA repair mechanisms that normally protects us against cancer no longer works adequately. Dutch researcher Najim Ameziane set out to find the genes responsible for this defect.

14 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

Clues about how blood forms could yield new strategies for treating blood diseases

Biologists have long wondered why the embryonic heart begins beating so early, before the tissues actually need to be infused with blood.

13 May 2009

Sanofi-aventis to acquire Oforta, oral chronic lymphocytic leukemia treatment

Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

12 May 2009

Iron deficiency in womb may delay auditory nervous system in preemies

Iron plays a large role in brain development in the womb, and new University of Rochester Medical Center research shows an iron deficiency may delay the development of auditory nervous system in preemies. This delay could affect babies ability to process sound which is critical for later language development in early childhood.

4 May 2009

First molecular-level numerical study of gene therapy

In a recent issue of The Journal of Chemical Physics , published by the American Institute of Physics (AIP), a group of researchers at the University of California, Berkeley and Los Alamos National Laboratory describe the first comprehensive, molecular-level numerical study of gene therapy.

29 Apr 2009

Dendrimers as synthetic gene vectors

29 Apr 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Change to Medicare reimbursement policy may pose risks to black kidney patients

A change in Medicare reimbursement policy could make it more difficult for African Americans with kidney disease to access dialysis services, suggests a study in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

23 Apr 2009

Anemia News and Research

Further Reading

Iron supplements for preventing or treating anemia among children in malaria-endemic areas

First baby born after new ovarian transplant technique

White House: Shield biotech drugs from generics for only seven years

Prevalence and predictors of antioxidant supplement use during breast cancer treatment

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Combination of gene therapy and induced pluripotent stem cells cure human genetic disease in vitro

Hospital refuses admission to young adults with thalassemia and sickle cell disease

Overnight dialysis more convenient and effective

Methylene blue in combo with new malaria drugs curbs the spread of malaria parasites

Rituximab linked to viral brain infection

Pathway opens up cure for Fanconi anemia

Cimzia approved in U.S. for rheumatoid arthritis

Clues about how blood forms could yield new strategies for treating blood diseases

Sanofi-aventis to acquire Oforta, oral chronic lymphocytic leukemia treatment

Iron deficiency in womb may delay auditory nervous system in preemies

First molecular-level numerical study of gene therapy

Dendrimers as synthetic gene vectors

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

Change to Medicare reimbursement policy may pose risks to black kidney patients

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News